GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Standard BioTools Inc (STU:FLB) » Definitions » Cyclically Adjusted Revenue per Share

Standard BioTools (STU:FLB) Cyclically Adjusted Revenue per Share : €2.79 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Standard BioTools Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Standard BioTools's adjusted revenue per share for the three months ended in Mar. 2024 was €0.142. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.79 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Standard BioTools's average Cyclically Adjusted Revenue Growth Rate was -5.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Standard BioTools was -9.70% per year. The lowest was -13.60% per year. And the median was -11.65% per year.

As of today (2024-05-27), Standard BioTools's current stock price is €2.30. Standard BioTools's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €2.79. Standard BioTools's Cyclically Adjusted PS Ratio of today is 0.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Standard BioTools was 2.73. The lowest was 0.28. And the median was 1.09.


Standard BioTools Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Standard BioTools's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools Cyclically Adjusted Revenue per Share Chart

Standard BioTools Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.78 2.68 2.67 3.09 2.94

Standard BioTools Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 2.95 2.99 2.94 2.79

Competitive Comparison of Standard BioTools's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Standard BioTools's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Standard BioTools's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Cyclically Adjusted PS Ratio falls into.



Standard BioTools Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Standard BioTools's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.142/131.7762*131.7762
=0.142

Current CPI (Mar. 2024) = 131.7762.

Standard BioTools Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.727 100.560 0.953
201409 0.819 100.428 1.075
201412 0.962 99.070 1.280
201503 0.868 99.621 1.148
201506 0.885 100.684 1.158
201509 0.887 100.392 1.164
201512 0.979 99.792 1.293
201603 0.902 100.470 1.183
201606 0.866 101.688 1.122
201609 0.680 101.861 0.880
201612 0.816 101.863 1.056
201703 0.816 102.862 1.045
201706 0.725 103.349 0.924
201709 0.602 104.136 0.762
201712 0.605 104.011 0.767
201803 0.527 105.290 0.660
201806 0.580 106.317 0.719
201809 0.633 106.507 0.783
201812 0.685 105.998 0.852
201903 0.456 107.251 0.560
201906 0.361 108.070 0.440
201909 0.346 108.329 0.421
201912 0.419 108.420 0.509
202003 0.355 108.902 0.430
202006 0.326 108.767 0.395
202009 0.467 109.815 0.560
202012 0.494 109.897 0.592
202103 0.369 111.754 0.435
202106 0.341 114.631 0.392
202109 0.318 115.734 0.362
202112 0.442 117.630 0.495
202203 0.312 121.301 0.339
202206 0.228 125.017 0.240
202209 0.328 125.227 0.345
202212 0.321 125.222 0.338
202303 0.297 127.348 0.307
202306 0.325 128.729 0.333
202309 0.300 129.860 0.304
202312 0.324 129.419 0.330
202403 0.142 131.776 0.142

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Standard BioTools  (STU:FLB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Standard BioTools's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.30/2.79
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Standard BioTools was 2.73. The lowest was 0.28. And the median was 1.09.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Standard BioTools Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Standard BioTools's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Standard BioTools (STU:FLB) Business Description

Traded in Other Exchanges
Address
2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080
Standard BioTools Inc manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. The company's segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Standard BioTools (STU:FLB) Headlines

No Headlines